PierreLorenzoTriozziMD
Oncology • Winston Salem, NCProfessor, Hematology & Oncology Cancer Biology Wake Forest Baptist Medical Center
Are you Dr. Triozzi?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Connect with colleagues in the same hospital or clinic
You already have 77 invites waiting! - Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
Medical Center Blvd
Winston Salem, NC 27157Phone+1 336-716-2255- Is this information wrong?
Summary
- Dr. Pierre Triozzi, MD is an oncologist in Winston Salem, North Carolina. He is currently licensed to practice medicine in North Carolina, Alabama, and Ohio. He is affiliated with Atrium Wake Forest Baptist and is a Professor at Hematology & Oncology Cancer Biology Wake Forest Baptist Medical Center.
Education & Training
Duke University HospitalFellowship, Hematology and Medical Oncology, 1983 - 1986- Duke University HospitalResidency, Internal Medicine, 1980 - 1983
Ohio State University College of MedicineClass of 1980
Certifications & Licensure
NC State Medical License 1980 - 2025
OH State Medical License 1986 - 2025
AL State Medical License 2000 - 2005- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- America's Top Doctors Castle Connolly, 2010-2014
- America's Top Doctors for Cancer Castle Connolly, 2009-2013
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011, 2013
Clinical Trials
- Vaccine Therapy in Treating Patients With Metastatic or Recurrent Cancer Start of enrollment: 2000 Mar 01
- A Phase I Study to Assess the Safety and Distribution of VB-111 in Patients With Advanced Metastatic Cancer Start of enrollment: 2007 Nov 01
- Dacarbazine and Recombinant Interferon Alfa-2b in Treating Patients With Primary Uveal Melanoma With Genetic Imbalance Start of enrollment: 2009 Nov 11
- Join now to see all
Publications & Presentations
PubMed
- Low-dose Paclitaxel with Pembrolizumab Enhances Clinical and Immunologic Responses in Platinum-refractory Urothelial Carcinoma.Bitting, R., Tooze, J., Goodman, M., Vile, D., Brown, J., Thomas, C., Neve, M., Kooshki, M., Dubey, P., Addo, S., Triozzi, P.> ;Cancer Research Communications. 2024 Feb 26
- Study protocol: phase II study to evaluate the effect of cetuximab monotherapy after immunotherapy with PD-1 inhibitors in patients with head and neck squamous cell ca...Burcher, K., Bloomer, C., Gavrila, E., Kalada, J., Chang, M., Gebeyehu, R., Song, A., Khoury, L., Lycan, T., Kinney, R., D'Agostino, R., Bunch, P., Shukla, K., Triozzi...> ;Therapeutic Advances in Medical Oncology. 2024 Jan 1
- 1 citationsQuad-shot-immunotherapy: quad-shot radiotherapy with pembrolizumab for advanced/recurrent head and neck cancer.Ryan T Hughes, Rediet R Gebeyehu, John Mason Kalada, Thomas W Lycan, Bart A Frizzell, Rebecca D Kinney, Ralph B D'Agostino, Paul M Bunch, Pierre Triozzi, Wei Zhang, Cr...> ;Future Oncology. 2023 Jul 1
- Join now to see all
Press Mentions
- CD138 Plasma Cells May Predict Brain Metastasis Recurrence Following Resection and Stereotactic RadiosurgeryOctober 7th, 2019
Grant Support
- Uveal Melanoma MicrometastasisNational Cancer Institute2009–2010
- Aav-Based Plasmacytoid Dendritic Cell Cancer VaccineNational Cancer Institute2006–2010
- Intratumoral Dendritic Cells PLUS Interleukin-2National Cancer Institute2001–2002
- Cellular Immunotherapy Of HIV Infection Using Autologous Lymph NodesNational Center For Research Resources1997–2001
- Chimeric HER-2 Peptide VaccineNational Cancer Institute2000
- Chimeric HER-2 Peptide VaccineNational Cancer Institute1999–2000
- Antigen Pulsed Dendritic Cell ImmunotherapyNational Cancer Institute1995–1997
- Phase IB Trial Of IL-2 Alone Or With Cytotoxic CellsDivision Of Cancer Treatment1991–1993
Hospital Affiliations
Atrium Wake Forest BaptistWinston Salem, North Carolina
